Growing Teratoma Syndrome (GTS) represents a rare and often confusing clinical phenomenon in pediatric oncology and gynecology. Specifically, physicians observe enlarging tumor masses during or after chemotherapy for malignant germ cell tumors. However, these patients simultaneously show declining or normalized serum tumor markers. This paradoxical growth frequently leads to a misdiagnosis of disease progression, which may result in unnecessary or harmful treatment modifications.

Understanding the Clinical Paradox of Growing Teratoma Syndrome

A recent case series highlighted two Black African females, aged 10 and 12 years, who presented with malignant ovarian tumors. Initially, both patients exhibited significantly elevated alpha-fetoprotein (AFP) and B-human chorionic gonadotropin (B-HCG) levels. Following the initiation of standard chemotherapy, their abdominal tumors continued to enlarge. Consequently, clinical teams initially feared treatment failure. However, their serum tumor markers continued to decline toward normal ranges, suggesting a biochemical response to therapy despite the physical growth.

Subsequent surgical removal of these progressing masses revealed mature teratoma components with no evidence of residual malignancy. This finding confirms that the enlarging masses consisted of benign, differentiated tissues. Furthermore, researchers suggest that chemotherapy may selectively destroy malignant cells while allowing benign teratomatous elements to flourish or mature. Therefore, maintaining a high index of suspicion is vital when imaging shows growth alongside falling markers.

Management and Prognosis of Growing Teratoma Syndrome

Early identification of this syndrome is essential to prevent the administration of ineffective and toxic salvage chemotherapy. Since mature teratomas are chemoresistant and radioresistant, complete surgical resection remains the gold standard of care. Moreover, the prognosis for patients with GTS is generally excellent once they undergo total excision. Surgeons must aim for clear margins to minimize the risk of local recurrence or future malignant transformation.

Frequently Asked Questions

What are the diagnostic criteria for Growing Teratoma Syndrome?

Diagnosis requires three specific criteria: an enlarging or new mass during or after chemotherapy for a non-seminomatous germ cell tumor, normalized or declining serum tumor markers (AFP/HCG), and histopathological confirmation of mature teratoma without malignant cells.

Why does the tumor grow if chemotherapy is working?

The growth occurs because chemotherapy successfully eliminates the malignant components, but the benign mature teratoma cells remain. These residual cells can expand or differentiate, creating the appearance of disease progression despite the loss of active malignancy.

How should clinicians follow up after surgery for GTS?

Long-term surveillance is necessary because mature teratomas can occasionally recur or undergo malignant transformation. Clinicians should use regular imaging and tumor marker monitoring to ensure early detection of any new developments.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Kiputa M et al. Growing teratoma syndrome of the ovary: a case series. J Med Case Rep. 2026 May 24. doi: 10.1186/s13256-026-06115-7. PMID: 42178587.


2. Logothetis CJ, et al. The growing teratoma syndrome. Cancer. 1982;50(8):1629-1635.


3. Li S, et al. Managing growing teratoma syndrome: new insights and clinical applications. Ecancermedicalscience. 2019;13:962.